Double-blind and randomized placebo-controlled trial of cerebrolysin in improvement of nerve function and living ability in patients with ischemic stroke
朱国行,洪震,姚景莉,俞丽云
DOI: https://doi.org/10.3321/j.issn:1673-8225.2003.22.018
2003-01-01
Abstract:Aim: To evaluate the clinical efficacy of cerebrolysin in treatment of patients with ischemic stroke in the early convalescent period. Methods: The trial was a multicenter, double-blind, randomized, parallel-controlled and prospective design. Sixty patients with ischemic stroke aged 45-80 years with the episode duration of (28 ± 7) d were randomly divided into cerebrolysin group (group A) and placebo group (group B) The results were assessed with scales including CSS, mini-mental state examination (MMSE), activities of daily living (ADL) and TLS. Results: Two cases were shed from the trial and the abscission and picking rates were 3% respectively. After treatment, the MMSE scores of the group A were 22.2 ± 5.6, superior to that of the group B (22.0 ± 6.6, P = 0.031 4). No significant difference was found in the other scores between the two groups. A significant difference was found in the scores of CSS, ADL, TLS and MMSE before and after treatment in the two groups respectively (CSS: group A 23.7 ± 6.3 vs 15.1 ± 8.8, group B 25.2 ± 6.8 vs 16.0 ± 8.1; ADL: group A 46.3 ± 7.0 vs 39.6 ± 12.8, group B 45.7 ± 9.4 vs 39.7 ± 11.6; TLS: group A 4.4 ± 0.8 vs 3.7 ± 1.3, group B 4.5 ± 0.8 vs 3.5 ± 1.3; MMSE: group A 17.8 ± 5.2 vs 22.2 ± 5.6, group B 20.0 ± 7.0 vs 22.0 ± 6.6. Conclusion: Cerebrolysin leads to clinical improvement in cognitive function of patients with ischemic stroke in the early convalescent period.
What problem does this paper attempt to address?